Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PuraPharmHKSE:01498 23 Shareholder Yield % is 16.34% as of Dec. 2025. GuruFocus rates HKSE:01498 with a GF Score™ of 23/100 and a GF Value™ of HK$0.51 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 968 Drug Manufacturers companies, PuraPharm ranks better than 95.76% on this metric.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, PuraPharm's Shareholder Yield % was 16.34%.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
PuraPharm Shareholder Yield % Related Terms
PuraPharm Shareholder Yield % Historical Data
* Premium members only.
The historical data trend for PuraPharm's Shareholder Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, PuraPharm's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PuraPharm Shareholder Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PuraPharm's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where PuraPharm's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
PuraPharm (HKSE:01498) has a Shareholder Yield % of 16.34% as of Dec. 2025. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on PuraPharm and its competitors. According to the industry distribution chart, PuraPharm ranks #41 out of 968 companies in the Drug Manufacturers industry, placing it in the top 4.2%.
Is PuraPharm's Shareholder Yield % too high?
PuraPharm's current Shareholder Yield % is 16.34%. The Drug Manufacturers industry median Shareholder Yield % is 0.30. PuraPharm's value of 16.34% is 5346.7% above this industry median. Based on the distribution chart, PuraPharm ranks #41 out of 968 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, PuraPharm has a GF Score™ of 23/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PuraPharm's Shareholder Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, PuraPharm ranks #41 out of 968 companies for Shareholder Yield %. This places PuraPharm in the top 4% of its industry — outperforming the majority of peers. The industry median Shareholder Yield % is 0.30. PuraPharm's value of 16.34% is 5346.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Drug Manufacturers company?
The median Shareholder Yield % among Drug Manufacturers companies is 0.30, based on 968 companies in the industry. Companies in the top quartile (top 25%) have a Shareholder Yield % significantly above this median, while those in the bottom quartile fall well below. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PuraPharm's current Shareholder Yield % of 16.34% is 5346.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on PuraPharm and its competitors. For the Drug Manufacturers industry, the median Shareholder Yield % is 0.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PuraPharm's current Shareholder Yield % is 16.34%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PuraPharm stock overvalued right now?
Based on GuruFocus' analysis, PuraPharm (HKSE:01498) is currently considered Possible Value Trap. The stock's GF Value™ is HK$0.51, compared to a current price of HK$0.28 — trading 45.1% below its estimated fair value. The current Shareholder Yield % is 16.34% and 5346.7% above the Drug Manufacturers industry median of 0.30. PuraPharm's overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For PuraPharm (HKSE:01498), the current Shareholder Yield % is 16.34% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PuraPharm (HKSE:01498) Overvalued in 2026?
Based on GuruFocus' analysis, PuraPharm stock appears to be undervalued.
The current stock price of HK$0.28 is trading 45.1% below its estimated GF Value™ of HK$0.51.
GuruFocus considers PuraPharm to be Possible Value Trap.
Key valuation signals for HKSE:01498:
Shareholder Yield %: 16.34%
GF Value™: HK$0.51 vs. price of HK$0.28 (45.1% below fair value)
Industry Position: 5346.7% above the Drug Manufacturers median (#41 of 968)
No single metric tells the full story. See the HKSE:01498 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PuraPharm Corporation Ltd is an investment holding company. Along with its subsidiaries, it is engaged in the research, development, production, and sale of concentrated Chinese medicine granules (CCMG) and other Chinese healthcare products. Its operations also include the cultivation and trading of raw Chinese herbs, the manufacture and sale of traditional Chinese medicine (TCM) decoction pieces, and the provision of Chinese medical diagnostic services. The Group's reportable operating segments are: China CCMG, Hong Kong CCMG, Chinese healthcare products, Clinics, and Plantation. Maximum revenue is derived from the Hong Kong CCMG segment. Geographically, the Group generates maximum revenue from Hong Kong, and the rest from the Chinese Mainland and other countries.
23GF Score
Get the complete analysis for HKSE:01498
Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01498 has been successfully added to your 
